Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses
Background Antibodies blocking programmed death (PD)-1 or its ligand (PD-L1) have revolutionized cancer care, but many patients do not experience durable benefits. Novel treatments to stimulate antitumor immunity are needed in the PD-(L)1 refractory setting. The stimulator of interferon genes (STING...
Saved in:
| Main Authors: | Shailender Bhatia, Paul Nghiem, Rima Kulikauskas, Candice Church, David M Koelle, Lisa Tachiki, Kimberly Smythe, Thomas Pulliam, Shira Tabachnick-Cherny, Saumya Jani, Peter H Goff, Rashmi Bhakuni, Brandon W Seaton |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/10/e009803.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy
by: Shailender Bhatia, et al.
Published: (2024-07-01) -
Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade
by: Shailender Bhatia, et al.
Published: (2025-08-01) -
Immunotherapy response in immunosuppressed patients with Merkel cell carcinoma: analysis of 183 patients
by: Paul Nghiem, et al.
Published: (2025-03-01) -
A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types
by: Zhen Zeng, et al.
Published: (2025-02-01) -
The conserved poxvirus membrane entry-fusion apparatus component OPG147 targets MITA/STING for immune evasion
by: Xue-Mei Yi, et al.
Published: (2025-06-01)